Skip to main content
Jane Buckner, MD, Rheumatology, Seattle, WA

Jane Hoyt Buckner MD


Physician

Join to View Full Profile
  • 1100 9th AveSeattle, WA 98101

  • Phone+1 206-223-6600

Dr. Buckner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Washington
    University of WashingtonFellowship, Rheumatology, 1995 - 1999
  • U Washington Affil Hosps
    U Washington Affil Hosps1992 - 1996
  • U Washington Affil Hosps
    U Washington Affil Hosps1992 - 1995
  • U Minnesota
    U Minnesota1991 - 1992
  • Minneapolis VA
    Minneapolis VA1990 - 1991
  • University of Minnesota
    University of MinnesotaResidency, Internal Medicine, 1987 - 1990
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1987
  • Carleton College
    Carleton CollegeB.A, Chemistry, Magna cum laude, 1983

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 1992 - 2027
  • MN State Medical License
    MN State Medical License 1989 - 1993
  • Rheumatology
    American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification HealthSentry EHR, Cerner Corporation, 2013
  • American College of Rheumatology Arthritis Investigator Award 1999 -2004, 2004
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Autoantibodies Against Neurologic Antigens in Nonneurologic Autoimmunity  
    Jane H Buckner, David A Hafler, Richard J Nowak, The Journal of Immunology
  • Citrullinated Aggrecan Epitopes as Targets of Auto‐Reactive CD4+ T Cells in Patients with Rheumatoid Arthritis  
    Jeffrey Carlin, Jane H Buckner, Eddie A James, Mariana J Kaplan, Arthritis & Rheumatology
  • Research Paper A Novel and Rapid Method to Quantify Treg Mediated Suppression of CD4 T Cells  
    Jane H. Buckner, Carmen Mikacenic, ScienceDirect
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Multiple alterations in IL-2R signaling contribute to decreased response to IL-2 in CD4+ T cells of T1D subjects as revealed by genotype/phenotype analysis.
    Long SA, Cerosaletti K, Shilling H, Zhang S, Zhang Z-Y, Pihoker C, Greenbaum C, Buckner J, Tolerance and Autoimmunity Keystone Symposium, Taos, NM
  • Rapamycin Promotes Induction of CD4+FoxP3+ T cells that Proliferate in Response to Common Gamma Chain Cytokines.
    Long SA, Van Landeghen M., Buckner, JH, Oral presentation, Federation of Clinical Immunology Societies (FOCIS) conference, San Diego, CA
  • Genetic Variation in PTPN22 Corresponds to Altered Signaling in B Lymphocytes.
    Arechiga AF, Buckner JH, American Association of Immunologists meeting, Miami, FL
  • Join now to see all

Lectures

  • Genotype-phenotype analysis reveals common disease mechanisms in autoimmunity. 
    University of California, San Francisco, and Genentech, San Francisco, CA
  • Update on Arthritis Research: Striving for a Cure Together. 
    The Arthritis Foundation, Pacific Northwest Chapter, Shoreline, WA
  • T Cell Immunoregulation. 
    University of Oxford, 14th EASD Oxford Workshop, Oxford, United Kingdom
  • Join now to see all

Other

Press Mentions

  • New Researcher Dr. Oliver Harrison at the Benaroya Research Institute at Virginia Mason Receives $2.9 Million NIH R01 Grant to Study How the Immune System Responds to the Microbiome
    New Researcher Dr. Oliver Harrison at the Benaroya Research Institute at Virginia Mason Receives $2.9 Million NIH R01 Grant to Study How the Immune System Responds to the MicrobiomeMarch 10th, 2021
  • The COVID-19 Immune Landscape Is Dynamically and Reversibly Correlated with Disease Severity
    The COVID-19 Immune Landscape Is Dynamically and Reversibly Correlated with Disease SeverityFebruary 1st, 2021
  • GentiBio Launches with $20M Seed Funding to Develop Engineered Regulatory T Cells for Autoimmune and Inflammatory Diseases
    GentiBio Launches with $20M Seed Funding to Develop Engineered Regulatory T Cells for Autoimmune and Inflammatory DiseasesAugust 7th, 2020
  • Join now to see all

Grant Support

  • T cells promoting transitions toward autoimmunityBENAROYA RESEARCH INST AT VIRGINIA MASON2023–2028
  • Regulatory T cells maintain immune homeostasis through translation controlBENAROYA RESEARCH INST AT VIRGINIA MASON2023–2028
  • Proteomic analysis of hydroxychloroquine prevention trials in T1D, RA and SLEBENAROYA RESEARCH INST AT VIRGINIA MASON2023–2028
  • T cells promoting transitions toward autoimmunityBENAROYA RESEARCH INST AT VIRGINIA MASON2023–2028
  • Proteomic analysis of hydroxychloroquine prevention trials in T1D, RA and SLEBENAROYA RESEARCH INST AT VIRGINIA MASON2023–2028
  • T cells promoting transitions toward autoimmunityBENAROYA RESEARCH INST AT VIRGINIA MASON2023–2028
  • Immune Tolerance Network: SUNBEAM Multi-year SupplementBENAROYA RESEARCH INST AT VIRGINIA MASON2014–2028
  • Immune Tolerance Network-NIDDK 2024 SupplementBENAROYA RESEARCH INST AT VIRGINIA MASON2014–2028
  • Immune Tolerance Network-NIDDK 2024 SupplementBENAROYA RESEARCH INST AT VIRGINIA MASON2014–2028
  • Immune Tolerance NetworkBENAROYA RESEARCH INST AT VIRGINIA MASON2014–2028
  • Immune Tolerance Network: SUNBEAM Multi-year SupplementBENAROYA RESEARCH INST AT VIRGINIA MASON2014–2028
  • T Cell Epigenomic Drivers of Disease Flares in Multiple SclerosisBENAROYA RESEARCH INST AT VIRGINIA MASON2024–2026
  • Harnessing engineered T regulatory cells to promote beta cell health in T1DBENAROYA RESEARCH INST AT VIRGINIA MASON2022–2026
  • Build to LEAD – Building partnerships to Link the Exposome to Autoimmune Disease (Admin Supp)BENAROYA RESEARCH INST AT VIRGINIA MASON2023–2025
  • Build to LEAD – Building partnerships to Link the Exposome to Autoimmune DiseaseBENAROYA RESEARCH INST AT VIRGINIA MASON2023–2025
  • Immune Tolerance NetworkBENAROYA RESEARCH INST AT VIRGINIA MASON2021–2025
  • Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapyBENAROYA RESEARCH INST AT VIRGINIA MASON2019–2025
  • Impact Of The Autoimmunity Associated PTPN22 1858tNational Institute Of Allergy And Infectious Diseases2011
  • Understanding Regulatory Defects T1d: Natural History And Impact Of TherapyNational Institute Of Diabetes And Digestive And Kidney Diseases2010
  • Impact Of The Autoimmunity Associated PTPN22 1858tNational Institute Of Allergy And Infectious Diseases2010
  • Linking Genetic Variation In The PTPN2 Gene To Autoimmune Disease SusceptibilityNational Institute On Drug Abuse2009–2010
  • Activation Induced Generation Of Human Regulatory T CellsNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2010

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: